Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
MYH9-related disease (MYH9-RD) is characterized by congenital macrothrombocytopenia, progressive kidney failure, and sensorineural hearing loss. We describe a patient with MYH9-RD and a normal platelet count. A 13-year-old boy with a normal platelet count presented with proteinuria and hematuria and underwent a kidney biopsy. Light microscopy showed mild mesangial matrix expansion. Electron microscopy showed thinning of the glomerular basement membrane and splitting of the lamina densa. A tentative diagnosis of Alport syndrome was made. Unexpectedly, genetic analysis revealed a de novo MYH9 gene variant (p.Gln1068_Leu1074dup). A peripheral blood smear examination showed giant platelets and leukocyte inclusion bodies, confirming a diagnosis of MYH9-RD. In summary, we described a patient with MYH9-RD without thrombocytopenia who showed glomerular basement membrane abnormalities similar to Alport syndrome. Peripheral blood smear examinations may be helpful for an appropriate diagnosis of MYH9-RD, even in patients with proteinuria and a normal platelet count.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11958883 | PMC |
| http://dx.doi.org/10.1007/s13730-024-00922-x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Value and validation of a nomogram model based on the Charlson comorbidity index for predicting in-hospital mortality in patients with acute myocardial infarction complicated by ventricular arrhythmias.
Zhong Nan Da Xue Xue Bao Yi Xue Ban
May 2025
Department of Cardiovascular Medicine, Affiliated Changsha Hospital of Xiangya School of Medicine, Central South University, Changsha 410005.
Objectives: The Charlson comorbidity index reflects overall comorbidity burden and has been applied in cardiovascular medicine. However, its role in predicting in-hospital mortality in patients with acute myocardial infarction (AMI) complicated by ventricular arrhythmias (VA) remains unclear. This study aims to evaluate the predictive value of the Charlson comorbidity index in this setting and to construct a nomogram model for early risk identification and individualized management to improve outcomes.
View Article and Find Full Text PDFEvaluation of different platelet-dependent von Willebrand factor activity assays to assess the in vivo inhibitory effect of caplacizumab on the von Willebrand factor-platelet interaction.
J Thromb Haemost
September 2025
Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, Milan, Italy; Università degli Studi di Milano, Department of Pathophysiology and Transplantation, Milan, Italy. Electronic address:
Background: Caplacizumab, a humanized anti-von Willebrand Factor (VWF) Nanobody®, is employed for immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) treatment. Its binding to the VWF A1 domain sterically inhibits VWF interaction with platelet glycoprotein Ib (GPIb), counteracting microthrombosis and accelerating the normalization of the platelet count. In caplacizumab-treated iTTP patients with bleeding episodes, measuring platelet-dependent VWF activity (VWF activity) is crucial for monitoring treatment with VWF concentrates.
View Article and Find Full Text PDFMicrovascular Occlusion and Postrecanalization Hyperperfusion in a Swine Model of Acute Ischemic Stroke.
J Am Heart Assoc
September 2025
Division of Experimental Cardiology, Department of Cardiology Erasmus MC University Medical Center Rotterdam The Netherlands.
Background: Despite successful recanalization after endovascular thrombectomy, more than half of patients with acute ischemic stroke with large-vessel occlusions experience an unsatisfactory outcome. Incomplete microvascular reperfusion may contribute to it, but its occurrence remains debated, partly due to clinical observations of hyperperfusion after recanalization. This study investigates the relationship between ischemia duration, infarct development, microclot presence, and cerebral perfusion in a swine model of focal cerebral ischemia and reperfusion.
View Article and Find Full Text PDFAssociation and Prognostic Implications of "No-Reflow Phenomenon" and Hypercoagulability in Patients With ST-Segment Elevation Myocardial Infarction.
JACC Asia
August 2025
Division of Cardiology, Department of Internal Medicine, Chung-Ang University College of Medicine, Seoul, South Korea; CAU Thrombosis and Biomarker Center, Chung-Ang University Gwangmyeong Hospital, Gwangmyeong, South Korea. Electronic address:
Background: Following percutaneous coronary intervention (PCI), the "no-reflow phenomenon" is associated with a worse outcome. However, it remains unclear how to prevent and treat this phenomenon during PCI.
Objectives: This study aimed to evaluate the association between thrombogenicity profiles and "no-reflow phenomenon" during primary PCI in patients with ST-segment elevation myocardial infarction (STEMI).
Diagnostic utility of hematological and biochemical markers for cystic echinococcosis in Tibetan patients of Sichuan, China.
Front Cell Infect Microbiol
September 2025
Department of Laboratory Medicine and Sichuan Provincial Key Laboratory for Human Disease Gene Study, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, China.
Objective: This hospital-based case-control study aims to evaluate hematological and biochemical markers for the diagnosis of cystic echinococcosis (CE) in the Tibetan population of Sichuan.
Methods: This study involved 83 patients diagnosed with CE and 45 healthy controls. Diagnosis of CE was confirmed through antibody and imaging tests, followed by an analysis of differences in blood and biochemical markers.